The general objectives of the CAMAC are: (a) To provide the biostatistical support to better understand the nature history of HIV infection (b) To conduct the appropriate biostatistical analyses to determine the risk factors, and appropriate interventions to limit the spread of the disease and to (c) biostatistically help characterize any biologic or environmental factors which will alter the natural history of the disease (e.g., either limit or accelerate the morbidity and mortality associated with infection) in this population. The specific objectives of the CAMAC study are: (1) To provide the biostatistical support to study the natural history of HIV infection among a population of homosexual men who analyzing the demographic, socio-cultural and behavioral self-report data and by statistically correlating this data with physical examination findings, HIV antibody status, immunologic and blood chemistry and hematology parameters and the presence of antibodies to other viruses. (2) To statistically estimate the rate of disease progression of infection by comparing laboratory findings (HLA-type, CBC, SMA-12), immunologic parameters (by flow cytometry), physical examinations, neuropsychiatric evaluations and electromechanical findings (EEG, EKG, MRI, CAT, nerve conduction studies, radiographic findings) with behavioral events. (3) To statistically estimate the rate of seroconversion among sexually homosexual men as well as determine those behaviors which may alter the rate of seroconversion. (4) To statistically estimate the nature and extent of co-virus infections among sexually active homosexual men.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Public Health & Prev Medicine
Schools of Public Health
United States
Zip Code
Galai, N; Vlahov, D; Margolick, J B et al. (1995) Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 8:66-74
Kirby, A J; Galai, N; Munoz, A (1994) Sample size estimation using repeated measurements on biomarkers as outcomes. Control Clin Trials 15:165-72
Kass, N E; Munoz, A; Chen, B et al. (1994) Changes in employment, insurance, and income in relation to HIV status and disease progression. The Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 7:86-91
Hoover, D R; He, Y (1994) Nonidentified responses in a proportional hazards setting. Biometrics 50:1-10
Hoover, D R; Black, C; Jacobson, L P et al. (1993) Epidemiologic analysis of Kaposi's sarcoma as an early and later AIDS outcome in homosexual men. Am J Epidemiol 138:266-78
McCarthy, B D; Wong, J B; Munoz, A et al. (1993) Who should be screened for HIV infection? A cost-effectiveness analysis. Arch Intern Med 153:1107-16
Graham, N M; Piantadosi, S; Park, L P et al. (1993) CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time. J Acquir Immune Defic Syndr 6:1258-66
Armenian, H K; Hoover, D R; Rubb, S et al. (1993) Composite risk score for Kaposi's sarcoma based on a case-control and longitudinal study in the Multicenter AIDS Cohort Study (MACS) population. Am J Epidemiol 138:256-65
Hoover, D R; Saah, A J; Bacellar, H et al. (1993) Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 329:1922-6